Picard Medical (PMI) shares updated 2026 investor deck
Rhea-AI Filing Summary
Picard Medical, Inc. (PMI) reported that on August 19, 2026 it released an updated investor presentation for use in investor relations and other communications. The presentation is provided as Exhibit 99.1 and is incorporated by reference.
The company states that this investor presentation and the related 8-K information are being furnished under Regulation FD and are not deemed “filed” for purposes of the Exchange Act or incorporated into Securities Act or Exchange Act filings by general reference language.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Investor presentation date: August 19, 2026
Exhibit 99.1: Investor Presentation (August 19, 2026)
Exhibit 104: Cover Page Interactive Data File
3 metrics
Investor presentation date
August 19, 2026
Date of the Picard Medical, Inc. investor presentation furnished as Exhibit 99.1
Exhibit 99.1
Investor Presentation (August 19, 2026)
Primary exhibit furnished with the current report
Exhibit 104
Cover Page Interactive Data File
Inline XBRL version of the cover page information
Key Terms
Regulation FD, emerging growth company, Inline XBRL
3 terms
Regulation FD regulatory
"Item 7.01 Regulation FD Disclosure On August 19, 2026, Picard Medical, Inc."
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"Cover Page Interactive Data File (formatted as Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
What did Picard Medical, Inc. (PMI) announce on August 19, 2026?
Picard Medical, Inc. announced that it published an updated investor presentation on August 19, 2026. The presentation is intended for investor relations and other purposes and is included as Exhibit 99.1 to this current report.
How is the new investor presentation for PMI being treated under SEC rules?
The investor presentation and related disclosure are furnished under Item 7.01 Regulation FD, not filed for Exchange Act liability. They are also not deemed incorporated by reference into any Securities Act or Exchange Act filing via general language.
Where can investors find Picard Medical’s August 19, 2026 investor presentation?
Investors can find the presentation as Exhibit 99.1 to the company’s current report dated August 19, 2026. The exhibit is titled “Investor Presentation (August 19, 2026)” and is incorporated by reference in the report.
What type of filing did Picard Medical, Inc. (PMI) use for this investor presentation?
Picard Medical, Inc. used a Form 8-K current report, specifically under Item 7.01 Regulation FD Disclosure. This item is commonly used to share investor presentations, slide decks, or other informational materials with the market.
Who signed the August 19, 2026 current report for Picard Medical, Inc. (PMI)?
The report was signed on behalf of Picard Medical, Inc. by Georgina Smith, the company’s Chief Accounting Officer. The signature indicates the company’s authorization of the furnished Regulation FD disclosure and accompanying exhibits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 19, 2026
(Exact name of registrant as specified in its charter)
|
|
|
|
||
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number) |
(IRS Employer
Identification No.)
|
|
|
|
(Address of principal executive offices, including zip code)
|
Registrant’s telephone number, including area code: (520 ) 545-1234
Not Applicable
(Former name or former address, if changed since last report)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On August 19, 2026, Picard Medical, Inc. (the "Company") published an investor presentation (the "Presentation") that it plans to use for investor relations and other purposes. A copy of the presentation is attached as Exhibit 99.1 and is incorporated herein by reference.
The information in this report and the exhibit attached hereto shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are being filed herewith:
|
Exhibit No.
|
Description
|
|
|
99.1
|
Investor Presentation (August 19, 2026) | |
|
104
|
Cover Page Interactive Data File (formatted as Inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Picard Medical, Inc. | |
|
|
By: |
/s/ Georgina Smith
|
|
Name:
|
Georgina Smith
|
|
| Title: |
Chief Accounting Officer
|
|
Dated: August 19, 2026
Exhibit 99.1
